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ABSTRACT 
Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early 
detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies 
based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic 
lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-
Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment 
of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung 
cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they 
are effective against eye metastasis. 
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INTRODUCTION 
Lung cancer remains underdiagnosed due to the lack of 
early-stage symptoms. Moreover, there are no blood 
markers for the early detection of lung cancer (unlike for 
cancers such as prostate, colorectal, and gynecological 
cancers) (1). In the past, non-specific cytotoxic agents 
were the first choice of treatment for patients with stage 
IV non-small-cell lung cancer (NSCLC; either 
adenocarcinoma or squamous cell carcinoma) (2, 3).  
However, in the last decade, novel molecular pathways 
have been found to be involved in adenocarcinoma and 
squamous cell carcinoma of the lung, and, as a result, 
targeted treatments are now being used. The most 
important of these are the treatments that target the 
epidermal growth factor receptor (EGFR), anaplastic 
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lymphoma kinase (ALK), serine/threonine-protein kinase 
B-Raf (BRAF), proto-oncogene tyrosine-protein kinase 
ROS (which is encoded by the ROS1 gene), c-Met proto-
oncogene protein (which is encoded by the MET gene), 
and RET proto-oncogene protein (which is encoded by 
the RET gene found on chromosome 10) (4, 5). An issue 
that has yet to be clarified is whether these targeted 
treatments are effective against eye metastasis. This 
issue is discussed in the following section, which is based 
on data that were obtained via a search of the US 
National Center for Biotechnology Information’s PubMed 
service on February 19, 2017. 
Overview of the Use of Targeted Treatments in Relation 
to Eye Metastasis 
Currently, oral tyrosine kinase inhibitors (TKIs) are being 
used to treat EGFR- and ALK-positive patients. In 
particular, for EGFR-positive patients, erlotinib, gefitinib, 
and afatinib (the first two of which are first-generation 
TKIs that target EGFR, and the third of which is a second-
generation TKI that targets EGFR) are the treatments of 
choice. If an EGFR-positive patient being treated with TKI 
experiences a relapse (as assessed using the Response 
Evaluation Criteria In Solid Tumors (RECIST) (6)), a 
rebiopsy should be performed (7). However, if the 
patient’s condition does not allow for a rebiopsy, a liquid 
biopsy should be performed (8). In particular, if the EGFR 
T790M mutation is detected, osimertinib (a TKI that 
targets EGFR) should be administered (9).  
Research indicates that gefitinib could be an effective 
agent against choroidal metastasis, and it should be used 
if such a metastasis exists (10). In the case of brain 
metastasis, research indicates that afatinib may be 
effective as a first-line treatment (11). Furthermore, a 
recent study showed that osimertinib was rapidly 
effective against brain metastasis, and it negated the 
need for radiotherapy (12). 
Regarding patients with ALK mutations, crizotinib (a TKI 
that targets ALK) is used as the first-line treatment (13). 
In particular, crizotinib has been shown to be effective 
against uveal and choroidal metastasis (14, 15). The 
human epidermal growth factor receptor 2 (HER2) has 
been found to be overexpressed in patients with lung 
cancer (16) and, in these cases, trastuzumab (a 
monoclonal antibody that targets HER2) may be 
administered (17). Research has indicated that this drug 
is able to control ocular metastasis (18). However, it is 
important to take into consideration that fact that 
trastuzumab can also induce adverse ocular effects (19).  
In addition to ALK mutations, BRAF mutations have been 
observed in patients with lung cancer (20). In these 
cases, the patients could be treated with ipilimumab (a 
monoclonal antibody that targets cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4)). In particular, 
ipilimumab has been successfully used for uveal 
metastasis (20-24). However, orbital myositis and 
retinopathy have been observed in patients treated with 
ipilimumab (22, 23), and other immunotherapies such as 
nivolumab and pembrolizumab (both of which are 
monoclonal antibodies that target programmed cell 
death protein 1 (PD-1)) are currently being tested (20, 
21).  
In some patients with lung cancer, the ROS1 pathway has 
been found to be upregulated (25). In these cases, 
crizotinib should be administered (26). Furthermore, 
research has indicated that eye metastasis that involves 
ROS1 upregulation can be efficiently controlled with 
crizotinib (14). Alternatively, cabozantinib (a TKI that 
targets c-Met and vascular endothelial growth factor 
receptor 2 (VEGFR-2)) can be used in cases involving 
crizotinib resistance (27).  
The RET pathway has also been found to be upregulated 
in some patients with lung cancer (25). In these cases, 
crizotinib (a TKI that targets ALK and ROS1) or alectinib (a 
TKI that targets ALK) should be administered (28, 29, 30) 
Cabozantinib may also be effective (31).  
Lastly, the c-Met pathway has been also shown to be 
upregulated in some patients with lung cancer (32). 
Furthermore, a previous study has suggested that, in 
patients with melanoma, c-Met overexpression is 
associated with uveal metastasis, but more data are 
required to clarify this association (34). A previous study 
indicated that crizotinib is effective against uveal 
metastasis that involves the upregulation of the c-Met 
pathway in a melanoma model (15). However, for NSCLC, 
cabozantinib should be used in cases involving 
upregulation of the c-Met pathway (33).  
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DISCUSSION 
Overall, the data on the use of TKIs or immunotherapy to 
control eye metastasis are limited. We recommend that 
if a patient experiences a cancer relapse, biopsies should 
be taken from the sites of relapse. We are currently 
waiting for trials with larger numbers of patients with 
BRAF, MET, RET, and ROS mutations. In these trials, data 
with the control of eye metastasis should be collected so 
that clear conclusions can be drawn regarding the 
optimum treatment approaches. 
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